Tag - PAVM

Markets

Cantor starts PAVmed at OW; PT $8

Cantor Fitzgerald initiated coverage of PAVmed (NASDAQ:PAVM) with an “overweight” rating and price target of $8. The stock closed at $3.93 on March 29. The company employs a unique business model that emphasizes capital...

March 29, 2021

Developments

PAVmed subsidiary gets breakthrough device designation for esophageal DNA test

PAVmed’s (NASDAQ:PAVM) subsidiary, Lucid Diagnostics, received FDA breakthrough device designation for its EsoGuard esophageal DNA test. The EsoGuard test, which is performed on esophageal samples collected using...

February 11, 2020

Tag - PAVM

Cantor starts PAVmed at OW; PT $8

PAVmed subsidiary gets breakthrough device designation for esophageal DNA test

General

More